The genetics of pediatric autoimmune diseases have been elucidated only partially. Multiple genetic factors are presumed to be involved in patients with well-characterized adult autoimmune rheumatic diseases, including systemic lupus erythematosus. By contrast, single causative genes have been identified for some pediatric autoimmune diseases. Autoimmune lymphoproliferative syndrome (ALPS) 1, 2 and certain primary immunodeficiency-associated autoimmune diseases, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy and immune dysregulation-polyendocrinopathy-enteropathy, X-linked syndrome, have been extensively studied.
ALPS is characterized by chronic lymphoproliferation combined with autoimmunity; mutations of molecules involved in FASdependent pathways play causative roles in this syndrome. The hallmarks of ALPS are an increased CD4/CD8 double-negative T (DNT) cell count and attenuated FAS-induced apoptosis. In addition to FAS mutations, FASLG and caspase-10 (CASP10) mutations are involved in ALPS. However, 20% of patients with ALPS are genetically unclassified. Patients with undetermined genetic alterations who fulfill the ALPS diagnostic criteria are classified as having ALPS-U. Some patients with ALPS-like syndromes harbor mutations in RAS or PRKCD. [3] [4] [5] Extensive clinical experience and research into the genetic basis of primary immunodeficiency with autoimmunity identified several ALPS-like patients. Genes involved in ALPS-like presentations have come to light in recent years, including PI3KD in patients with activated PI3 kinase delta syndrome (APDS), signal transducer and activator of transcription 3 (STAT3) gain-of-function mutation, LPS-responsive beige-like anchor protein (LRBA) deficiency, and cytotoxic T lymphocyteassociated protein 4 (CTLA4) haploinsufficiency. [6] [7] [8] [9] [10] [11] [12] [13] TNF-a-induced protein 3 (TNFAIP3, A20) functions as a negative regulator of the nuclear factor kB (NF-kB) pathway and 14 The IKK complex contains 2 catalytic subunits (IKKa and IKKb) and a subunit that regulates the canonical NF-kB pathway (NEMO/IKKg), whereas IKKa regulates the noncanonical pathway. Ubiquitin-induced recruitment of TNFAIP3 (A20) to NEMO is sufficient to block IKK phosphorylation. 15 On activation, IKK phosphorylates the inhibitory IkBa protein, leading to its degradation and dissociation from NFkB, which translocates to the nucleus.
14 Therefore TNFAIP3 (A20) dysfunction leads to activation of the NF-kB pathway.
Here, whole-exome sequencing (WES) analysis of patients with ALPS-like disease identified a germline mutation of TNFAIP3 as a causative factor for ALPS-U.
METHODS

Cell culture
Control and patient-derived PBMCs were cultured as activated T cells. PBMCs were stimulated with anti-CD2, anti-CD3, and anti-CD28 beads, according to the manufacturer's protocol (Miltenyi Biotec, Gladbach, Germany), and expanded with ALyS505N-0 Medium (Cell Science & Technology Institute, Miyagi, Japan) supplemented with 10% FBS and 50 g/mL recombinant human IL-2 (PeproTech, Rocky Hill, NJ).
Genome analysis
Genomic analysis was performed after obtaining informed consent from each patient. The genetic analysis was approved by the Tokyo Medical and Dental University Ethics Committee (protocol no. 103).
WES analysis was performed, as previously described. Briefly, genomic DNA was fragmented, and exonic sequences were enriched by using SureSelect Target Enrichment with the SureSelect Human All Exon 38 Mb kit (Agilent, Santa Clara, Calif). 16 The captured fragments were purified and sequenced on an Illumina Hiseq2000 platform by using paired-end reads. Bioinformatics analysis was performed with an in-house algorithm based on published tools. Identified single nucleotide variants were filtered with dbSNP versions 131 and 132, the 1000 Genomes Project database, an in-house SNP database, and the Human Genetic Variation Database. The frequency of identified single nucleotide variants was also searched in the Japan Reference Genome and Exome Aggregation Consortium databases.
Western blotting
Aliquots containing 1 3 10 6 cells were washed with PBS and lysed in RIPA buffer (150 mmol/L NaCl, 1.0% NP-40, 0.1% SDS, 0.1% sodium deoxycholate, 5 mmol/L EDTA, and 10 mmol/L Tris-HCl, pH 7.4) containing protease inhibitors. Proteins were separated by using SDS-PAGE and transferred to membranes, and blots were probed with the following primary antibodies: anti-TNFAIP3, anti-phospho-IKKa/b Ser176/180, anti-IKKa, anti-phosphoIkBa Ser32, anti-IkBa, anti-phospho-NF-kB p65 Ser536, anti-NF-kB p65, anti-phospho-p38 mitogen-activated protein kinase (MAPK), anti-p38 MAPK, anti-SMC1 (all from Cell Signaling, Danvers, Mass), anti-glyceraldehyde-3-phosphate dehydrogenase, anti-CASP3 (GeneTex, Irvine, Calif), anti--green fluorescent protein (GFP; TaKaRa Clontech, Siga, Japan), or anti-b-actin (Sigma-Aldrich, St Louis, Mo). Primary antibodies were detected with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (GE Healthcare, Little Chalfont, United Kingdom).
Subcellular fractionation
Aliquots containing 1 3 10 6 cells were washed with PBS and lysed in hypotonic buffer (10 mmol/L HEPES, pH 7.5; 10 mmol/L potassium acetate; 1.5 mmol/L magnesium acetate; 2.5 mmol/L dithiothreitol; and 0.05% NP-40) containing protease inhibitors. Lysates were centrifuged at 720g (3000 rpm) for 5 minutes. The resulting pellets contained the nuclear fraction, whereas the supernatants constituted the cytoplasmic fraction. The pellets were washed with 500 mL of hypotonic buffer, and the nuclear fraction was fractionated by using nuclear extraction buffer (20 
ELISA
ELISA was performed with a human IL-10, IL-18, or Fas ligand/TNFSF6 quantikine ELISA kit (R&D Systems, Minneapolis, Minn) and a human B cell-activating factor ELISA kit (Abcam, Cambridge, United Kingdom).
Proliferation assay
PBMCs were labeled with 3 mmol/L carboxyfluorescein succinimidyl ester (eBioscience, San Diego, Calif) for 5 minutes at room temperature and stimulated for 3 days with 1 or 0.1 mg/mL anti-CD3 and anti-CD28 antibodies (BD PharMingen, San Jose, Calif) or 5 mg/mL PHA (Sigma-Aldrich). Then cells were stained for CD4 and CD8 (Miltenyi Biotec, Bergisch Gladbach, Germany) and analyzed by using flow cytometry.
RESULTS
Case description
A 7-month-old Japanese boy had a fever and was found to have increased levels of C-reactive protein. The patient was treated with antibiotics, which had no significant effect. After spontaneous resolution of the fever, liver dysfunction was transiently observed for 2 months. The patient presented to the hospital at 1 year of age with fever, cervical lymph node swelling, and skin rash. Bilateral cervical lymphadenopathy and hepatosplenomegaly were noted (Fig 1, A and B) . Because the fever persisted for more than 5 days, the patient was given a diagnosis of Kawasaki disease and treated with intravenous immunoglobulin infusion therapy; however, intravenous immunoglobulin was not effective. Relevant laboratory data are listed in Table I . 16 Complete blood cell count revealed thrombocytopenia, and marked hypergammaglobulinemia was detected. Results of tests for various autoantibodies, including anti-double-stranded DNA (dsDNA) antibody and anti-single-stranded DNA (ssDNA) antibody, were positive. Cytokine profiling analysis revealed increased IL-10, soluble FAS ligand, and IL-18 levels, which complied with the ALPS diagnostic criteria. 17 Serum B cell-activating factor levels were normal. 18 The patient had an extensive skin rash, and skin biopsy specimens showed infiltration of CD4 1 and CD8
1 T cells (Fig 1, C) . Because of the patient's transient hepatic dysfunction, a liver biopsy was performed, which revealed the presence of interface hepatitis with spotty focal necrosis and giant multinucleated hepatocytes. Marked CD8 1 T-cell infiltration was observed (Fig 1, D) . Treatment with prednisolone and cyclosporine relieved the clinical symptoms, with regression of the lymphadenopathy and normalization of the complete blood cell count and serum IgG levels. However, recurrence of liver dysfunction was detected. Administration of mycophenolate mofetil instead of cyclosporine with prednisolone ameliorated the liver dysfunction, and the patient remained symptom free.
Immunologic characteristics
The patient's DNT cell population was 5.1% of T-cell receptor ab 1 cells (Fig 2) and 15.4% of total lymphocytes (2.86 3 10 8 cells/L). In addition, DNT cells were B220
, which is characteristic of ALPS (see Fig  E1, A, in this article's Online Repository at www.jacionline. org). Immunologic profiles of the patient's lymphocytes obtained by using flow cytometry are shown in Table E1 in this article's Online Repository at www.jacionline.org. Patients with ALPS show impaired marginal zone B-cell (IgM memory B-cell) function. 19 The present case showed reduced marginal zone B (IgM memory B) cells (1.0% of lymphocytes and 4.6% of memory B cells) with normal class-switched memory B-cell levels Age-matched normal range is shown, except as follows: *normal range from a nonage-matched control subject; reference range cited from Janda et al. 16 BAFF, B cell-activating factor; dsDNA, double-stranded DNA; GBM, glomerular basement membrane; sFASL, soluble FAS ligand; ssDNA, single-stranded DNA. (see Fig E1, B) . However, isohemagglutinin antibody levels were normal (Table I) . Expansion of CD21 low B cells in the peripheral blood is observed in patients with common variable immunodeficiency and systemic lupus erythematosus and can be associated with autoimmunity. 20 However, the CD21 low CD20 1 population was normal (8.9% of CD20 1 cells and 1.34% of lymphocytes) in this patient (see Fig E1, B) . Analysis of T cells showed reduced T H 1 cell levels (0.98% of lymphocytes). DNT cells from patients with ALPS show features of terminally differentiated effector memory T cells re-expressing CD45RA 1 (TEMRA) but are CD27
1
CD28
1 KLRG1 2 and do not express the transcription factor T-bet. 21 However, in the present case the central memory, naive, TEMRA, and effector memory subpopulations of CD3
1
CD8
1 T cells were normal (see Fig E1, B) .
Genetic analysis
Immunologic data and the patient's phenotype supported a diagnosis of ALPS. However, the patient was negative for mutations in FAS, FASL, CASP10, KRAS, NRAS, and PRKCD. In addition, somatic FAS mutation was not detected in purified DNT cells (data not shown), and the FAS-dependent apoptosis pathway was intact (see Fig E2 in this article' s Online Repository at www.jacionline.org). This led us to hypothesize that the genes involved in this patient's disease were independent of the FAS pathway. A possible diagnosis for this patient was ALPS-U according to the International ALPS Workshop 2009 criteria. 17 Therefore WES analysis was performed to identify the causative gene. Mutations associated with ALPS-like phenotypes, such as PI3KCD, CTLA4, LRBA, and STAT3 gain-of-function mutations, were not identified. Fig 3 shows the filtering process used to narrow down candidate genes. A complete list of candidate genes is provided in Supplemental Data E1 in this article's Online Repository at www.jacionline.org. One of the candidate genes identified was TNFAIP3 (A20). This patient carried a heterozygous c.1245_1248del (NM_001270507) causing a p. glutamine (Gln) 415 frameshift mutation of TNFAIP3 ([A20] ;  Fig 4, A-C) . This mutation has not been reported in any Control and patient-derived PBMCs were stimulated with 10 ng/mL TNF-a for 15 minutes. Unstimulated and stimulated samples were analyzed. MFI, Mean fluorescence intensity. C, Western blot analysis of control and patient-derived activated T cells. Cells were harvested at the indicated time points after stimulation with 10 ng/mL TNF-a. D, Nuclear accumulation of NF-kB. Cells were harvested at 15 minutes after stimulation with 10 ng/mL TNF-a. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase. E, MAPK activation in response to TNF-a stimulation as in Fig 5, C. database, including the National Center for Biotechnology Information, Human Genetic Variation Database, Japan Reference Genome, 1000 Genomes, and Exome Aggregation Consortium databases. The mutation was identified at the germline level (Fig 4, D) , and mutations were identified as de novo mutations (see Fig E3 in this article' s Online Repository at www. jacionline.org).
Expression of TNFAIP3 (A20)
Truncation of TNFAIP3 (A20) by frameshift mutation generates a protein of 415 amino acids. Western blot analysis was performed by using an antibody that recognizes peptide around glycine at codon 276 of TNFAIP3 (A20) to determine whether this short form was expressed in patient-derived cells. The results showed reduced expression of TNFAIP3 (A20) and a lowmolecular-weight band that was detected only in patientderived cells (Fig 4, E) . These results suggested that the p. Gln 415 frameshift mutation can result in escape from nonsensemediated decay and expression of TNFAIP3 as a truncated protein.
NF-kB pathway activation in patient-derived cells
Next, to examine NF-kB pathway activity, IKK phosphorylation and NF-kB activation under basal culture conditions were compared between control and patient-derived activated T cells. The phosphorylation of IKK and NF-kB was increased in patientderived cells (Fig 5, A) . Assessment of NF-kB activation in control and patient-derived unstimulated peripheral blood T cells showed that NF-kB phosphorylation was increased in patientderived unstimulated T cells to a level similar to that in TNFa-stimulated control T cells (Fig 5, B) . Next, the kinetics of NF-kB activation were investigated by using control and patient-derived activated T cells. Stimulation with TNF-a activated the NF-kB pathway, with marked downregulation of IkBa expression, and these effects were more pronounced in patient-derived cells than in control cells (Fig 5, C) . NF-kB is activated by phosphorylation and translocate into the nucleus. Therefore NF-kB nuclear translocation was investigated by means of cellular fractionation. NF-kB nuclear translocation was increased in patient-derived cells in the absence of TNF-a stimulation. In addition, TNF-a stimulation-dependent NF-kB nuclear translocation was increased in patient-derived cells (Fig  5, D) . Enhanced MAPK pathway activation after TNF-a stimulation was also observed in patient-derived cells (Fig 5, E) .
Deubiquitination activity was impaired in mutant TNFAIP3 (A20) TNFAIP3 (A20) is a deubiquitinating enzyme that cleaves the Lys63-linked ubiquitin chains of its substrates, including NEMO/ IKKg, RIP1, and TRAF6. To determine whether the TNFAIP3 (A20) mutants retained their deubiquitinase function, WT or mutant TNFAIP3 (A20) was cotransfected into 293T cells with HA-tagged Lys63-linked ubiquitin, and TRAF6 ubiquitination was assessed by means of Western blotting. Mutant TNFAIP3 (A20)-transfected cells showed increased TRAF6 polyubiquitination, suggesting the loss of function of TNFAIP3 (A20) deubiquitination activity in the mutant protein (Fig 6) .
NF-kB pathway activation leading to cellular proliferation
NF-kB pathway activation accelerates cellular proliferation. Tcell receptor-dependent or PHA-dependent cellular proliferation was compared between control and patient-derived T cells by using the carboxyfluorescein succinimidyl ester assay. Patientderived CD4 and CD8 T cells exhibited increased T-cell proliferation in response to CD3 and CD28 stimulation (Fig 7, A) . Next, spontaneous cell growth in normal T-cell expansion medium without CD2, CD3, and CD28 stimulation was measured. Cell proliferation rates were higher in patient-derived activated T cells than in control cells. However, patient-derived cells showed increased spontaneous cell death (Fig 7, B) . Patient-derived activated T cells also showed increased CASP activation (Fig 7, C) . DISCUSSION TNFAIP3 (A20) heterozygous knockout mice appear normal without evidence of pathology; however, TNFAIP3 (A20) homozygous knockout mice show severe inflammation, are hypersensitive to both LPS and TNF, and die prematurely. 22 The human TNFAIP3 (A20) locus and its polymorphisms are associated with certain conditions, such as Crohn disease, rheumatoid FIG 6 . Impaired deubiquitinase function of mutant A20. Cells were collected at 48 hours after transfection, and equal amounts of whole-cell lysates were subjected to immunoprecipitation by using TRAF6 antibody. High-molecular-weight ubiquitin aggregates (top) of the precipitates were detected by means of immunoblotting with anti-HA antibody. Cell lysates were also blotted with anti-TRAF6, anti-green fluorescent protein (GFP), and anti-b-actin antibodies to monitor the amounts of precipitant and loading amounts and to evaluate transfection efficiency. MT, Mutant type.
arthritis, systemic lupus erythematosus, psoriasis, and type 1 diabetes. 23 These findings further illustrate the importance of TNFAIP3 (A20) in the resolution of inflammation and the prevention of human disease.
During the preparation of this manuscript, Zhou et al 24 reported heterozygous germline mutations in TNFAIP3 (A20) in 6 unrelated families with early-onset systemic inflammation. The disorder resembles Behçet disease. In these reported cases patients have autoinflammation at ages ranging from 7 months to 16 years. All patients had oral and genital ulcers, and some cases were positive for autoantibodies. Although family 2 exhibited hemolytic anemia or immune thrombocytopenia and strong autoantibody positivity, no lymphadenopathy was described. Furthermore, patients in family 2 showed skin involvement similar to that in the present case. Skin involvement is relatively rare in patients with typical ALPS or ALPS-like diseases. This phenotype might help identify TNFAIP3 (A20) mutations in patients with ALPS-U.
We previously reported that TNFAIP3 (A20) is a common genetic target in B-lineage lymphomas, especially in patients with diffuse large B-cell lymphoma. 25 In addition to its role in diffuse large B-cell lymphoma, TNFAIP3 (A20) is frequently inactivated by somatic mutations and/or deletions in patients with mucosaassociated tissue lymphoma and Hodgkin lymphoma. This finding supports loss of TNFAIP3 (A20), leading to lymphoproliferation. On the other hand, A20 stably interacts with CASP8 and FAS-associated via death domain in HTLV-I-infected cells and supports the growth of HTLV-I-infected cells. Depletion of TNFAIP3 (A20) leads to CASP activation and cell death. 26 In our previous report WT TNFAIP3 (A20), but not the mutant form, suppressed tumor growth. 25 In the present study cell proliferation and cell death were increased in patient-derived cells. NFkB functions as an antiapoptotic factor but is also required for apoptosis induction, especially in the setting of activationinduced cell death. 27 Our observations and those of Saitoh et al 26 can be explained by the balance between cell survival signals associated with NF-kB activation and cell death caused by CASP activation resulting from decreased TNFAIP3 (A20). Complete knockdown of TNFAIP3 (A20) might also be more toxic and dead (right graph) cell numbers are shown. Numbers of live and dead cells were counted daily by using a hemocytometer after Trypan blue staining. Initially, cells were seeded at a density of 1 3 10 6 cells/mL. One half of the medium supernatant was replaced on day 3. C, Western blot analysis of control and patientderived activated T cells. *P < .05 (Mann-Whitney U test).
than haploinsufficiency of TNFAIP3 (A20). The phenotype of this patient characterized by autoinflammation might be explained by increased cell proliferation and cell death caused by reduced TNFAIP3 (A20) expression. Lymphoproliferation and autoimmunity caused by TNFAIP3 (A20) loss of function are consistent with the phenotype of ALPS. This is the first reported case of ALPS-U caused by haploinsufficiency of TNFAIP3 (A20) by frameshift germline mutation. This discovery bridges the gap between leukemia/lymphoma development and autoimmunity, autoinflammation, or both.
